We generate revenue primarily from (i) consumer ophthalmic services and (ii) basic ophthalmic services. Our consumer ophthalmic services include refractive correction (including presbyopia correction), myopia control and provision of optical products and services, the costs for which are generally borne by customers. Our basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, which may be covered by public health insurance programs. In light of upgraded social consumption in China over the recent years, we plan to increase our strategic focus on our consumer ophthalmic services business and devote more efforts to pursue a continued rapid growth, while maintaining the fundamental strength of our basic ophthalmic business.
We have a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of consumer ophthalmic services. We focus on the quality of our ophthalmic services and devote resources to allow our ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. We are also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility.
Cutting-edge technology and equipment is another key factor underpinning our market leadership. Our patients are treated by ophthalmologists with latest technologies and advanced equipment. According to the Frost & Sullivan Report, we are the first-mover in Inner Mongolia to offer PDT to treat age-related macular degeneration, to use micropulse laser technology to treat macular edema, to use phacoemulsification technology to treat cataract, to use minimally invasive vitreoretinal surgeries to treat vitreous and ocular fundus diseases, and to use artificial vitreous body implantations to protect the eye from atrophy. We are a leader in Inner Mongolia to first introduce advanced medical equipment, such as OPTOS ultra-widefield fundus imaging system, vitreous cutter, cataract phacoemulsifier, excimer laser, VisuMax femtosecond laser, optical coherence tomography for blood flow quantification, microfield detector and corneal confocal microscopy. We believe that our Baotou Hospital is the one-and-only ophthalmic hospital in Inner Mongolia with a preparation room to produce hospital-made traditional Chinese medicine capsules and eye drops. In particular, we are one of the few medical service providers in China that are qualified to produce 0.01% atropine sulfate eye drops to be prescribed within the respective hospitals to control myopia among adolescents.